Monte Rosa Therapeutics, Inc. (GLUE) stock
GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07−0.09 (-0.98%)
Close on Nov 17, 2026Market cap $773.79MP/E –Yield –
Monte Rosa Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Monte Rosa Therapeutics's price to book ratio was 1.8× on Nov 11, 2026, against 4.1× a year earlier. Over the last 5 years it ranged from 0.8× to 5.4×, with a median of 1.5×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.8× | −2.1 |
| 2025 | Dec 31, 2025 | 3.9× | +1.9 |
| 2024 | Dec 31, 2024 | 2.1× | +0.5 |
| 2023 | Dec 29, 2023 | 1.5× | +0.3 |
| 2022 | Dec 30, 2022 | 1.3× | −1.3 |
| 2021 | Dec 31, 2021 | 2.6× | – |
See a number that looks wrong?